Objective: We compared responses to bolus infusion of 5% albumin (ALB) or normal saline (NS) for hypotension in neonates.
Introduction
Hypotension in neonates is a common clinical problem and is felt, in the absence of perinatal blood loss, to be associated with immaturity of vasomotor tone, depressed myocardial function, and possibly relatively insufficient adrenal response to stress. [1] [2] [3] [4] [5] Although there are many questions regarding definition, treatment and outcome of neonatal hypotension, a common practice is to initially treat with judicious volume therapy. 2, 3, 6 If the response is inadequate to reach normotension, vasopressor therapy, in the form of dopamine or dobutamine, is often initiated. Several clinical studies comparing colloid versus crystalloid bolus therapy for the treatment of hypotension have been performed, but these studies have been underpowered to show a difference between these two therapies. 7, 8 Recommendations for the use of normal saline (NS) for bolus therapy in neonates have been based on these small clinical studies as well as the perception that NS therapy is cheaper than albumin (ALB) therapy.
7-9
Methods This randomized, double-blinded study compared clinical responses to bolus infusions of either colloid or crystalloid fluid therapy for hypotension. The study was approved by the Institutional Review Board at West Virginia University, and all procedures were in accordance with the ethical standards of the committee and with the Helsinki's Declaration of 1975 as revised in 1983. Colloid therapy was in the form of 5% ALB and crystalloid therapy in the form of NS. ALB is a sterile solution of pooled human protein, separated from plasma by cold-alcohol fractionation processes. It is iso-osmotic with human plasma. The sodium content ranges from 130 to 160 meq l À1 , while the K content is <2 meq l
À1
. This product is heat treated to inactivate viruses, including Hepatitis species and there are no added preservatives. No cross matching and no cellular matching are required for use. Infectious potential for this product is low. NS is sterile, 0.9% salt water with a pH of 4.5 to 7.0. The NaCl ion content is 154 meq l À1 and is considered isotonic with human plasma. No other solutes or preservatives are present. NS carries a negligible infectious risk.
This study included infants admitted to the NICU service at West Virginia University Children's Hospital at less than 24 h old. The criteria for entry into the study included a diagnosis of hypotension with a mean arterial blood pressure less than the 5th percentile for at least 10 min. Criteria for hypotension were in relation to normative values based on birthweight published by Versmold et al. 10 for neonates. Parental consent was obtained for all participants. Exclusion criteria included culture-confirmed sepsis, acute perinatal blood loss, suspected or confirmed renal or cardiac anomalies, hydrops fetalis, need for blood-product transfusion during the study period or clinical status prohibiting adherence to stepwise protocol (including need for high-frequency ventilation and diagnosis of pulmonary hypertension).
Arterial blood-pressure measurements were assessed using transducers attached to umbilical or peripheral arterial lines when available or measured by noninvasive, electronic cuff pressure monitor (Dinamap) when arterial access was not available. The randomization was performed by a pharmacist using a computer code that was generated after obtaining a written informed consent. The study group assignment was blinded to caregivers in the NICU. The fluid was sent to the NICU in a syringe concealed by an opaque wrapper.
The infants were given 10 ml kg À1 of NS or ALB intravenously over 20 min. Baseline arterial blood pressure was recorded prior to the bolus and monitored continuously for the remainder of the study period. If the infants were noted to be hypotensive at anytime during this period, a second bolus of the same fluid was given in the same manner. If hypotension continued or returned after a second bolus, vasopressor therapy in the form of dopamine could be initiated.
Before initiating this study, we assumed that there would be no distinct benefit from either NS or ALB. Assuming this null hypothesis, a power analysis revealed with 85% confidence that 100 patients would be required to detect a 20% difference in therapies. The primary outcome measure for this study was the improvement in arterial blood pressure toward normal (greater than the 10th percentile for mean arterial blood pressure for weight) at 1 h after the infusion of fluid. Secondary measures included the degree of improvement toward the 50th percentile (represented as a score ranging from no change ¼ 0 to arterial blood pressure reaching the 50th percentile of mean arterial blood pressure for weight ¼ 1.00) duration in hours of normotension following the first bolus, qualification for a second bolus, the duration in hours of normotension following the second bolus, the qualification for vasopressor therapy and urine output, (measured by the weight of the diapers every 2 h for a total of 6 h postinfusion). Other clinical data were also compared. These included survival to discharge, mean length of hospital stay, mean days on a ventilator and days on supplemental oxygen, occurrence of all intraventricular hemorrhage (IVH) and occurrence of high grade (grade 3, or 4) IVH. In addition, the pharmacy costs (ALB, NS, dopamine) and direct nursing costs for the therapies were compared. The nursing time was computed based on the time required to prepare the medication, any mixing with diluent, filling of connecting tubing and setting up an infusion pump. The nursing cost applied included the salary plus fringe benefits for the average nursing salary in the neonatal intensive care unit.
All of these measures were compared by the Pearson's w 2 -test or by the analysis of variance (ANOVA) as indicated in Table 2 . IVH rates were compared to data from our NICU during the study period using t-test.
Results
A total of 101 infants completed the study, 49 in the ALB group and 52 in the NS group. Birthweight and gestational age were similar in both groups. At baseline, mean arterial blood pressure measurements were in the hypotensive range and were similar in both groups (Table 1) . Primary and secondary responses are detailed in Table 2 .
As stated previously, the primary measure of response was the improvement of arterial blood pressure to a normal value (greater than the 10th percentile of mean arterial blood pressure for weight) at 1 h from the start of the infusion. Of those infants randomized to ALB-bolus therapy, 57.1% achieved a normal arterial blood pressure at 1 h, compared to 32.1% of those infants randomized to NS therapy (P ¼ 0.01).
We also compared several secondary responses. At 1 h after bolus therapy, babies given ALB showed a greater degree of improvement compared to NS treated infants In the ALB-treated group, arterial blood-pressure improvement score was 0.24±0.04 compared to a score of 0.14 ± 0.02 for the NS group (P ¼ 0.006). Continued hypotension with qualification for a second bolus did not differ from the ALB and NS groups. However, the duration of normotension after the second bolus and the subsequent qualification for vasopressor therapy both favored the ALB-treated group. Duration of normotension after a second bolus was significantly longer for the ALB-treated group, with ALB averaging 15.2 ± 11.0 h versus 9.5 ± 10.9 h duration after a second NS bolus (P ¼ 0.04). The subsequent need for vasopressor therapy also favored the ALB-treated group with 24.5% of the infants in the ALB group meeting the criteria for vasopressor therapy versus 44.2% of the NS-treated infants (P ¼ 0.03). Urine output measured for 6 h after bolus was not different. There were no differences in survival also, length of hospital stay or pulmonary morbidities between the two treatment groups.
Infants less than 1500 g had at least one head ultrasound as part of their routine care. During the 5-year-study period, the overall IVH rate was 17% (81/480) with 4.3% having grade 3 or 4 hemorrhages (21/480). These rates are within the ranges of the reported incidences of 25 to 30% for all IVH and less than 10% for grade 3 to 4 IVH from the Vermont Oxford database. 11 For the ALB-treated infants, the overall rate of any IVH was 28% with 8% being grade 3 or 4. These were not different from the total population (P ¼ 0.5). For the NS-treated group, the overall rate of any IVH was 45.2% with 22.6% being either grade 3 or 4. Both of these rates were significantly higher (P<0.05) than the reported rates of hemorrhage from our unit. In over 70% of these cases (both ALB and NS groups), the infants failed bolus therapy and had received dopamine infusion.
In the cost analysis, the average expense per patient for treating the hypotension was $63.98 ± 8.03 for the ALB group and $62.18±8.58 for the NS group (ns). The average amount of nursing time required for preparation for each of the infusions was 8.5±0.6 min for ALB and 9.9±0.6 min for NS (ns).
Discussion
Hypotension is a common problem in premature neonates, but unfortunately, the precise definition of low arterial blood pressure in neonates has not been clearly established. [1] [2] [3] 10 The etiology of hypotension also is not completely clear, but is felt to be related to immature vascular tone and/or myocardial depression. [1] [2] [3] 12 Volume loss is rarely involved, and is usually associated with a low hematocrit and/or a significant perinatal history. 6 More recently, there is some evidence that relatively insufficient adrenal responses may be involved. [1] [2] [3] 5, 13 Many questions remain about what arterial blood pressure levels are truly associated with end-organ ischemia, whom and when to treat as well as what therapy should be first line and how much should be given.
14-18 The Versmold criteria for arterial blood pressure determination during the first day of life, in spite of being one of the oldest published arterial blood pressure graphs for premature infants seems to be quite accurate. Data from a large group of premature newborns (over 200 000 infants) collected by Clark shows similar mean and confidence intervals as the Versmold data. 19 For our study, we applied a strict limit on volume boluses to 20 ml/kg À1 . Infants who were likely to receive additional volume were not eligible for the study. Infants with hydrops or confirmed sepsis, therefore at risk for capillary leak syndrome, were excluded from participation. Infants on high-frequency ventilation and those with significant pulmonary hypertension were not eligible due to our inability to strictly control fluid and/or vasopressor therapy as well as variability of cardiac function in these infants.
Regardless of the absence of clear data for or against bolus therapy, present clinical practice for hypotension includes initial treatment with limited fluid therapy when the arterial blood pressure is below the standard values. 1, 3, 6, 17 Most authors recommend NS for this bolus therapy.
1,3,6 -9 There has been considerable debate in the adult medical literature regarding which solution is more effective under certain clinical conditions. Proponents for colloid therapy note the importance of maintaining intravascular oncotic pressure to prevent extravasation of fluid into tissue. 20 There is considerably less data from the neonatal population. Studies have been small and results have been equivocal. NS is also chosen based on a significantly lower cost than ALB. [7] [8] [9] One of the driving forces for treatment of neonatal hypotension is the worry that hypotension may be related to IVH in lowbirthweight infants. [14] [15] [16] Babies receiving ALB had IVH rates that were not significantly different from IVH rates within our NICU and published averages, 11 but infants receiving NS had significantly higher percent of both total and high-grade IVH. We speculate that it is unlikely that the NS infusion itself was responsible for this higher rate, but rather it is possible that the degree of hypotension in this group was a factor. As stated previously, above 70% of these infants who developed IVH, regardless of treatment, had remained hypotensive through two bolus infusions of fluid and also qualified for dopamine therapy. The longer duration of hypotension and/or the use of dopamine infusion might have contributed to this higher rate of IVH. Because, infants treated with ALB were less likely to qualify for dopamine, the incidence of IVH was less. Certainly, this is an area that requires further evaluation, especially with the more frequent use of NS in the clinical arena.
Another commonly raised concern has been a suspected relationship between ALB administration and pulmonary edema formation in neonates. This concern is largely based on a report from the 1970s. 21 In this report, six critically ill infants had a worsening of respiratory symptoms after ALB administration. As confounding comorbidities, these infants had clinical evidence of respiratory distress syndrome and were all treated with oxygen but without any positive-airway pressure. This latter circumstance might have increased the likelihood of pulmonary edema regardless of the ALB infusions. A study by Bignall et al., 22 demonstrated no change in blood gases or oxygenation associated with ALB infusion. They concluded that there was no evidence of pulmonary edema associated with ALB infusion. 22 Two neonatal studies have prospectively compared NS to ALB in clinical settings that were similar to ours. In the study by So et al., 7 63 infants with hypotension were randomized to receive up to 30 ml kg À1 of ALB or NS and subsequently treated with vasopressor. They concluded that there was no increased benefit with ALB and reported more weight gain in infants who had received ALB. No other clinical measurement of tolerance differed significantly between the two groups and they did not report differences in respiratory status. A second study, by Oca et al., 8 compared NS and 5% ALB for the treatment of hypotension in 41 neonates. This study showed no difference in short-term response of rise in arterial blood pressure. However, they looked at the arterial blood-pressure response only at 30 min after administration. Neither of these authors detailed whether their studies were powered to show the results that were presented. Indeed, the authors of 'Cochrane review of colloid versus crystalloid' concluded that none of the studies reviewed showed adequate power for their conclusions. 9 For our analysis, we began with some baseline estimates for the power estimation. We powered our study to detect a 20% difference between the two therapies and followed through to get an adequate number of participants.
As stated previously, a common concern about ALB-bolus therapy continues to be a concern about ALB and pulmonary edema. Although our study did not specifically investigate pulmonary edema within our study population, we did compare pulmonary comorbidities that included days on the ventilator, days of supplemental oxygen as well as overall survival and length of hospital stay in the two groups. There were no significant differences between the two groups for any of these factors (Table 2) .
We have demonstrated that a normotensive state can be achieved more often with ALB compared to NS-bolus therapies. Although there was no difference in the number of subjects who qualified for a second bolus, there was a significant increase in the duration of normotension after a second bolus of ALB versus NS. Perhaps most importantly, the use of ALB-bolus resulted in a significant reduction in the use of dopamine therapy to maintain normotension. This last finding is a potentially important result that has previously been overlooked in previous studies. The use of pressors requires a considerable escalation in the infant's support and monitoring and also increases the therapeutic risks to the patients. 23 From our data, it appears that the infants who received 20 ml kg À1 NS and dopamine infusion had a very high rate of IVH. Besides these safety concerns, the reduction in the use of dopamine infusion to treat the ongoing hypotension is a factor that reduces the total cost of therapy when ALB is compared to NS. Factoring the extra cost of dopamine along with increased nursing time into the total cost estimate equalized the costs for both treatment options.
We conclude that neonates with hypotension are more likely to respond favorably after ALB-bolus therapy compared to NS. ALB appears safe and also cost neutral compared to NS-bolus therapy. There is a longer duration of normotension after 20 ml kg À1 of ALB versus an equal volume of NS and the significant reduction in the use of dopamine. These findings along with a higher incidence of IVH in the NS treated infants may make ALB-bolus therapy a preferred therapy for the normalization of uncomplicated hypotension in neonates during the first day of life.
